venerdì 29 maggio 2020

FDA Approves Nivolumab Plus Ipilimumab and Chemotherapy for First-Line Treatment of Metastatic NSCLC - Evidence for efficacy is based on the results from the CHECKMATE-9LA study

Fonte: ESMO European Society for Medical Oncology

Link all'articolo completo